Article info
Original research
Combination of weekly paclitaxel-carboplatin plus standard bevacizumab as neoadjuvant treatment in stage IB–IIB cervical cancer
- Correspondence to Professor Ignace Vergote, University Hospital Leuven, Department of Gynaecology and Obstetrics, Division of Gynaecological Oncology, Katholieke Universiteit Leuven, Leuven 3000, Flanders, Belgium; ignace.vergote{at}uz.kuleuven.ac.be
Citation
Combination of weekly paclitaxel-carboplatin plus standard bevacizumab as neoadjuvant treatment in stage IB–IIB cervical cancer
Publication history
- Received January 26, 2021
- Revision received March 26, 2021
- Accepted March 31, 2021
- First published April 15, 2021.
Online issue publication
April 24, 2022
Article Versions
- Previous version (7 June 2021).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© IGCS and ESGO 2021. No commercial re-use. See rights and permissions. Published by BMJ.